邻苯二甲酸钙水合物 | 5793-85-1

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 邻苯二甲酸钙水合物
• 中文别名: 鄰苯二甲酸鈣；酞酸钙水合物；?苯二甲酸?
• CAS: 5793-85-1
• 化学式: C8H6CaO4
• 分子量: 206.21
• InChiKey: GUCNQULWIBUQDJ-UHFFFAOYSA-N

物化性质

• 稳定性/保质期：

  在常温常压下，该物质保持稳定。

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2917399090

文献信息

• [EN] THERMOPLASTIC POLYMER COMPOSITION<br/>[FR] COMPOSITION DE POLYMÈRE THERMOPLASTIQUE
  申请人：MILLIKEN & CO

  公开号：WO2015042561A1

  公开（公告）日：2015-03-26

  The invention provides a thermoplastic polymer composition comprising a polyolefin polymer and a nucleating agent. The nucleating agent comprises a compound conforming to the structure of Formula (I). The invention also provides a series of compounds encompassed by the structure of Formula (I).

  这项发明提供了一种热塑性聚合物组合物，包括聚烯烃聚合物和成核剂。该成核剂包括符合式(I)结构的化合物。该发明还提供了一系列符合式(I)结构的化合物。
• Amorphous Coprecipitates of Atorvastatin Pharmaceutically Acceptable Salts
  申请人：Dixit Girish

  公开号：US20110142883A1

  公开（公告）日：2011-06-16

  The present invention relates to stable amorphous co-precipitates of atorvastatin pharmaceutically acceptable salts with pharmaceutically acceptable excipients, method for the preparation, pharmaceutical compositions, and method of treating thereof. Advantageously, the amorphous co-precipitates of atorvastatin pharmaceutically acceptable salts of the present invention have improved physiochemical characteristics that assist in the effective bioavailability

  本发明涉及阿托伐他汀药物可接受盐与药物可接受辅料的稳定非晶共沉淀物、制备方法、制药组合物及其治疗方法。有益的是，本发明的阿托伐他汀药物可接受盐的非晶共沉淀物具有改善的物理化学特性，有助于有效的生物利用度。
• Novel Polymorph of Atorvastatin Calcium and Use Thereof for the Preparation of Amorphous Atorvastatin Calcium
  申请人：Dixit Girish

  公开号：US20100260851A1

  公开（公告）日：2010-10-14

  The present invention provides a novel polymorphic form of atorvastatin calcium, designated as form Al, process for preparation, pharmaceutical compositions, and method of treating thereof. The present invention further provides a process for the preparation of highly pure amorphous atorvastatin calcium using the novel atorvastatin calcium form Al. The present invention also relates to novel amorphous form of atorvastatin tert-butyl ester, chemically known as [R-(R*,R*)]-2-(4-fluorophenyl)-[β],[δ]-dihydroxy -5-(1-methylethyl)-3-phenyl-4-(phenylcarbamoyl-1H-pyrrole-1-heptanoicacid tert-butyl ester, process for the preparation, and its application for preparing highly pure atorvastatin and its pharmaceutically acceptable salts thereof. The present invention also relates to use of the novel amorphous atorvastatin tert-butyl ester and novel atorvastatin calcium form al for preparing amorphous atorvastatin calcium.

  本发明提供了阿托伐他汀钙的一种新的多晶形式，称为Al型，制备方法、制药组合物和治疗方法。本发明还提供了一种使用新的阿托伐他汀钙Al型制备高纯非晶态阿托伐他汀钙的方法。本发明还涉及阿托伐他汀叔丁基酯的新非晶态形式，化学名称为[R-(R*，R*)]-2-(4-氟苯基)-[β]，[δ]-二羟基-5-(1-甲基乙基)-3-苯基-4-(苯基羰氨基)-1H-吡咯烷-1-庚酸叔丁基酯，制备方法及其应用于制备高纯阿托伐他汀及其药用盐。本发明还涉及使用新的非晶态阿托伐他汀叔丁基酯和新的阿托伐他汀钙Al型制备非晶态阿托伐他汀钙。
• PHARMACEUTICAL COMPOSITION AND A METHOD FOR ITS MANUFACTURE
  申请人：KOTIN Oleg Arkadyevich

  公开号：US20210228677A1

  公开（公告）日：2021-07-29

  Disclosed is a storage stable pharmaceutical composition containing at least one active pharmaceutical ingredient selected from peptides of the general formula 1 [SEQ ID NO: 1-144] or peptides of the general formula 2 [SEQ ID NO: 145-288], or, their derivatives, analogs or pharmaceutically acceptable salts, or co-crystals of these peptides, their derivatives or analogues; and a pharmaceutically acceptable carrier, wherein the composition retains at least 80% of the potency of active pharmaceutical ingredient in the pharmaceutical composition after storage for at least four months at room temperature. Also, disclosed are process for their preparation and methods of use.

  本发明公开了一种储存稳定的药物组合物，包含至少一种从一般式1 [SEQ ID NO: 1-144]的肽或一般式2 [SEQ ID NO: 145-288]的肽中选择的活性药物成分，或其衍生物、类似物或药学上可接受的盐，或这些肽、其衍生物或类似物的共晶体；以及药学上可接受的载体，其中该组合物在室温下储存至少四个月后，仍保持至少80％的活性药物成分的效力。此外，还公开了其制备方法和使用方法。
• Polymer separation membrane
  申请人：——

  公开号：US20030110947A1

  公开（公告）日：2003-06-19

  A separation membrane comprising a polyether polymer having a weight-average molecular weight of 10 4 to 10 7 and obtained by polymerizing an oxirane compound of the formula: 1 wherein R is a hydrogen atom; an alkyl group, an alkyl group having an halogen atom, or —CH 2 O(CH 2 CH 2 O) k —R′ (R′ is a group selected from an alkyl group, an alkenyl group, a cycloalkyl group, an aryl group and an aralkyl group; k is from 0 to 12.); or an ethylenically unsaturated group, a reactive silicon-containing group or a methylepoxy-containing group, is excellent in mechanical strength and flexibility.

  一种分离膜，包括一种聚醚聚合物，其重均分子量为104至107，通过聚合式1的环氧化合物制得：其中R为氢原子；烷基，带有卤素原子的烷基，或—CH2O（CH2 ）k—R′（R′为从烷基、烯基、环烷基、芳基和芳基烷基中选择的基团；k为0至12.）；或乙烯基不饱和基团、反应性含硅基团或甲基环氧基团。该分离膜具有优异的机械强度和柔韧性。